Chemodenervation is Associated With Reduced Mental Health Disorders in Patients With Synkinesis
Otolaryngology–Head and Neck Surgery · 2024
DOI: 10.1002/ohn.936 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, 2024. Written by Fred Jeffrey Lorenz and 2 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. Major MEDLINE topics: Facial Paralysis, Synkinesis. Cited 10 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCATS NIH HHS.
Abstract (original language)
Objective
To compare the prevalence of mental health disorders in individuals with facial synkinesis, facial paralysis alone, and the general population. Study Design Retrospective cohort.
Setting
Eighty‐two health care organizations across the United States.
Methods
The TriNetX Research Network was queried from 2011 to 2021 for patients with facial paralysis without synkinesis, facial paralysis and documented synkinesis, and controls, matched for age, sex, race, and ethnicity. Cases included infectious, iatrogenic, or idiopathic facial paralysis. Patients with pre‐existing depression or anxiety were excluded. Two‐year rates of newly diagnosed depression, anxiety, and mental health prescriptions were compared.
Results
Among 127,573 patients with facial paralysis, 92.5% (n = 117,976) had facial paralysis alone, and 7.5% (n = 9597) also had documented synkinesis. Compared to controls, patients with facial paralysis alone had increased risks of new depression (8.9% vs 7.3%, P < .001) and anxiety (10.1% vs 9.6%, P < .001), with higher mental health medication rates (16.6% vs 13.1%, P < .001). Patients with documented synkinesis, in comparison to controls, had the highest risks of depression (19.8% vs 8.6%, P < .001), anxiety (20.5% vs 10.5%, P < .001), and prescriptions (28.1% vs 15.8%, P < .001). The 27.8% (n = 2669) of synkinetic patients treated with chemodenervation had lower rates of depression (8.5% vs 23.5%, P < .001), anxiety (9.0% vs 23.8%, P < .001), and prescriptions (21.6% vs 30.0%, P < .001) compared to synkinetic patients who were not.
Conclusion
Facial paralysis, particularly synkinesis, is linked to increased mental health disorders. Integrating mental health screening and treatment into a comprehensive approach is crucial. Chemodenervation is associated with decreased mental health disorders in synkinesis, highlighting its therapeutic potential.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
ORCID profiles: Jessyka G Lighthall
Funding
- NCATS NIH HHS
Cite
APA
Lorenz, F. J., Schopper, H. K., & Lighthall, J. G. (2024). Chemodenervation is Associated With Reduced Mental Health Disorders in Patients With Synkinesis. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.936
Vancouver
Lorenz FJ, Schopper HK, Lighthall JG. Chemodenervation is Associated With Reduced Mental Health Disorders in Patients With Synkinesis. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.936
BibTeX
@article{Lorenz2024,
author = {Lorenz, Fred Jeffrey and Schopper, Heather K and Lighthall, Jessyka G},
title = {Chemodenervation is Associated With Reduced Mental Health Disorders in Patients With Synkinesis},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2024},
doi = {10.1002/ohn.936}
}
EUVIMED